Prognostic assays for maintenance hemodialysis patients
AssigneesQuest Diagnostics Investments Incorporated, Los Angeles Biomedical Research Institute
InventorsKamyar Kalantar-Zadeh, Michael P. Caulfield, Wael A. Salameh
Life of this patent
Estimating the term…
Abstract
Described herein are methods for determining the overall survival of maintenance hemodialysis patients. The methods include measuring low density lipoprotein (LDL) particle size and subfraction concentrations as prognostic tools for early mortality risk detection. For example, the presence of increased very small LDL concentration or decreased LDL particle size in blood-serum serves as a useful means for prognostic risk assessment and monitoring.
Claims21
A method for predicting mortality risk in a maintenance hemodialysis (MHD) patient comprising:
- a. separating lipoprotein particles from non-lipoprotein particles in a sample from a MEM patient,
- b. irradiating the lipoprotein particles with alpha radiation and fractionating the lipoprotein particles according to particle diameter using ion mobility fractionation,
- c. determining the large low density lipoprotein (1-LDL) concentration in the sample from the patient by detecting and counting the fractionated lipoprotein particles having a particle diameter of 220.0-233.3 A, and
- d. identifying the patient as having reduced risk of mortality when the sample 1-LDL concentration is greater than a reference 1-LDL concentration or identifying the patient as having no change in the risk of mortality when the sample 1-LDL concentration is less than the reference 1-LDL concentration.
A method for predicting mortality risk in a maintenance hemodialysis (MHD) patient comprising:
- a. separating lipoprotein particles from non-lipoprotein particles in a plasma sample from an MHD patient,
- b. irradiating with alpha radiation and fractionating the lipoprotein particles according to particle diameter using ion mobility lipoprotein fractionation,
- c. determining the low density lipoprotein (LDL) particle concentrations by detecting and counting the fractionated lipoprotein particles having a particle diameter of 180.0-233.3 Å in the sample from the patient,
- d. determining a mean low density lipoprotein particle diameter (LDL-Pd) in the sample from the MHD patient based on the concentrations of LDL particles in the sample,
- e. determining the total LDL concentration (LDL-C) in the sample, and
- f. identifying the patient as having increased risk of mortality when the sample mean LDL-Pd is less than the reference LDL-Pd and the sample LDL-C is greater than a reference LDL-C, or identifying the patient as having no change in the risk of mortality when the sample LDL-Pd is greater than or equal to the reference LDL-Pd.
Dependencies are inferred from the claim text.